HIV-1 tat, Recombinant (Human Immunodeficiency Virus-1)

Human immunodeficiency virus type-1 (HIV-1) regulatory Trans-Acting Transcription factor (TAT) plays an essential role in viral replication and infectivity. In addition, during acute infection, Tat is released extracellularly by infected cells and is taken up by neighboring cells where it transactivates viral replication and increases virus infectivity.\n\nRecombinant HIV-I TAT is a single, non-glycosylated, polypeptide chain containing 86 amino acids encoded by two exons and having chain having a molecular mass of 14kD. \n\nSpecificity:\nReacts with anti-Tat (HIV-1) antibodies from human, monkey, rabbit and mouse serum.\n\nStorage and Stability:\nLyophilized powder may be stored at 4 degrees C for short-term only. Reconstitute to nominal volume by adding sterile dH2O, aliquot and store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

H6007-09

Size

10ug

Form

Supplied as a lyophilized powder. No additives.\nReconstitution: Reconstitute with sterile 18MOmega-cm H2O > 0.1mg/ml.

Purity

Purified by column chromatography ((same/more than) 90% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain).\nEndotoxin: (same/less than) 0.1ng/ug (IEU/ug) of HIV-I TAT.

References

1. HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. Gavioli R, Gallerani E, Fabris M, Marastoni M, J Immunol 2004 Sep 15;173(6):3838-43 2. Full-length HIV-1 Tat protein necessary for a vaccine. Opi S, Peloponese JM Jr, Watkins J, Yirrell DL, Vaccine 2004 Aug 13;22(23-24):3105-11 3. Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application. Caputo A, Brocca-Cofano E, De Michele R, Rolen U, Tondelli L, Vaccine 2004 Jul 29;22(21-22):2910-24 4. Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. Urbinati C, Bugatti A, Zoppetti G, Presta M, FEBS Lett 2004 Jun 18;568(1-3):171-7 5. Furin cleavage of the HIV-1 Tat protein. Tikhonov I, Ruckwardt TJ, Hatfield GS, FEBS Lett 2004 May 7;565(1-3):89-92 6. Fusion of HIV-1 Tat protein transduction domain to poly-lysine as a new DNA delivery tool. Hashida H, Miyamoto M, Hida Y, Kondo S, Br J Cancer 2004 Mar 22;90(6):1252-8.